company background image
JAZZ

Jazz PharmaceuticalsNasdaqGS:JAZZ Stock Report

Last Price

US$136.76

Market Cap

US$8.4b

7D

-5.2%

1Y

-18.9%

Updated

23 Jan, 2022

Data

Company Financials +
JAZZ fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance0/6
Financial Health2/6
Dividends0/6

JAZZ Stock Overview

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally.

Jazz Pharmaceuticals Competitors

Viatris

NasdaqGS:VTRS

US$17.6b

Harmony Biosciences Holdings

NasdaqGM:HRMY

US$2.0b

Assertio Holdings

NasdaqCM:ASRT

US$91.9m

AbbVie

NYSE:ABBV

US$233.3b

Price History & Performance

Summary of all time highs, changes and price drops for Jazz Pharmaceuticals
Historical stock prices
Current Share PriceUS$136.76
52 Week HighUS$189.00
52 Week LowUS$117.64
Beta0.94
1 Month Change6.69%
3 Month Change-4.15%
1 Year Change-18.91%
3 Year Change7.74%
5 Year Change14.46%
Change since IPO671.35%

Recent News & Updates

Shareholder Returns

JAZZUS PharmaceuticalsUS Market
7D-5.2%-2.5%-6.1%
1Y-18.9%5.3%4.2%

Return vs Industry: JAZZ underperformed the US Pharmaceuticals industry which returned 5.3% over the past year.

Return vs Market: JAZZ underperformed the US Market which returned 4.2% over the past year.

Price Volatility

Is JAZZ's price volatile compared to industry and market?
JAZZ volatility
JAZZ Average Weekly Movement4.7%
Pharmaceuticals Industry Average Movement10.6%
Market Average Movement6.7%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.4%

Stable Share Price: JAZZ is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: JAZZ's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20031,940Bruce Cozaddhttps://www.jazzpharma.com

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer.

Jazz Pharmaceuticals Fundamentals Summary

How do Jazz Pharmaceuticals's earnings and revenue compare to its market cap?
JAZZ fundamental statistics
Market CapUS$8.41b
Earnings (TTM)-US$160.90m
Revenue (TTM)US$2.86b

2.9x

P/S Ratio

-52.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
JAZZ income statement (TTM)
RevenueUS$2.86b
Cost of RevenueUS$206.13m
Gross ProfitUS$2.66b
ExpensesUS$2.82b
Earnings-US$160.90m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-2.62
Gross Margin92.80%
Net Profit Margin-5.62%
Debt/Equity Ratio159.9%

How did JAZZ perform over the long term?

See historical performance and comparison

Valuation

Is Jazz Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: JAZZ ($136.76) is trading below our estimate of fair value ($565.45)

Significantly Below Fair Value: JAZZ is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: JAZZ is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: JAZZ is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate JAZZ's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: JAZZ's PB Ratio (2.1x) is in line with the US Pharmaceuticals industry average.


Future Growth

How is Jazz Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?

44.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: JAZZ is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: JAZZ is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: JAZZ's is expected to become profitable in the next 3 years.

Revenue vs Market: JAZZ's revenue (8.3% per year) is forecast to grow slower than the US market (9.1% per year).

High Growth Revenue: JAZZ's revenue (8.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: JAZZ's Return on Equity is forecast to be high in 3 years time (22.2%)


Past Performance

How has Jazz Pharmaceuticals performed over the past 5 years?

-15.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: JAZZ is currently unprofitable.

Growing Profit Margin: JAZZ is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: JAZZ is unprofitable, and losses have increased over the past 5 years at a rate of 15.7% per year.

Accelerating Growth: Unable to compare JAZZ's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: JAZZ is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).


Return on Equity

High ROE: JAZZ has a negative Return on Equity (-4.09%), as it is currently unprofitable.


Financial Health

How is Jazz Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: JAZZ's short term assets ($2.6B) exceed its short term liabilities ($735.1M).

Long Term Liabilities: JAZZ's short term assets ($2.6B) do not cover its long term liabilities ($7.8B).


Debt to Equity History and Analysis

Debt Level: JAZZ's net debt to equity ratio (142.9%) is considered high.

Reducing Debt: JAZZ's debt to equity ratio has increased from 127% to 159.9% over the past 5 years.

Debt Coverage: JAZZ's debt is not well covered by operating cash flow (12.5%).

Interest Coverage: JAZZ's interest payments on its debt are well covered by EBIT (3.2x coverage).


Balance Sheet


Dividend

What is Jazz Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate JAZZ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate JAZZ's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if JAZZ's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if JAZZ's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of JAZZ's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure


CEO

Bruce Cozadd (57 yo)

19yrs

Tenure

US$12,573,300

Compensation

Mr. Bruce C. Cozadd serves as Member of Board of Advisors at Cellares Corp. He co-founded Jazz Pharmaceuticals Public Limited Company in 2003 and has been Chairman and Chief Executive Officer since April 2...


CEO Compensation Analysis

Compensation vs Market: Bruce's total compensation ($USD12.57M) is above average for companies of similar size in the US market ($USD6.49M).

Compensation vs Earnings: Bruce's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: JAZZ's management team is considered experienced (2.4 years average tenure).


Board Members

Experienced Board: JAZZ's board of directors are considered experienced (9.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: JAZZ insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.3%.


Top Shareholders

Company Information

Jazz Pharmaceuticals plc's employee growth, exchange listings and data sources


Key Information

  • Name: Jazz Pharmaceuticals plc
  • Ticker: JAZZ
  • Exchange: NasdaqGS
  • Founded: 2003
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$8.407b
  • Shares outstanding: 61.47m
  • Website: https://www.jazzpharma.com

Number of Employees


Location

  • Jazz Pharmaceuticals plc
  • Waterloo Exchange
  • Fifth Floor
  • Dublin
  • Co. Dublin
  • 4
  • Ireland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/23 23:14
End of Day Share Price2022/01/21 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.